Business
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
About this update from Nextcure, Inc.
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The virtual KOL Event is accessible here. The event featured: Beryl Manning-Geist, MD (Emory University)Ursula Matulonis, MD (NextCure Scientific Advisory Board and Dana-Farber Cancer Institute)Rakesh Dixit, PhD, DABT (NextCure Scientific Advisory Board) Discussion centered on first reported clinical efficacy data from the Phase 1 dose escalation study of SIM0505 in ovarian cancer and uterine serous carcinoma (USC), two gynecologic malignancies where effective treatment options remain limited. About SIM0505 at the Annual Meeting of the American Society for Clinical Oncology (ASCO 2026) Materials from NextCure's ASCO 2026 activities are available on the Company's website under Investor Relations, Events & Presentations: ASCO Poster: https://ir.nextcure.com/static-files/1f2a6660-e197-4a65-859d-b9a9d7085234ASCO Press Release: https://ir.nextcure.com/news-releases/news-release-details/nextcure-presents-positive-sim0505-phase-1-dose-escalation-dataVirtual KOL Event Replay: https://lifescievents.com/event/gkso204j/Virtual KOL Event Presentation: https://nextcure-preview.gcs-web.com/static-files/1fe1f78d-cd2a-4656-a542-a916574b0217 Beryl Manning-Geist, MD is an assistant professor in the Division of Gynecologic Oncology in the Department of Gynecology and Obstetrics at Emory University School of Medicine. Dr. Manning-Geist specializes in treating patients with gynecologic cancers including uterine, ovarian and cervical cancers. She practices at Winship Cancer Institute at Emory Midtown. After working at the National Institutes of Health’s National Cancer Institute, Dr. Manning-Geist attended Emory University School of Medicine on a full scholarship as a Woodruff Scholar. There, she received her MD summa cum laude before completing her residency in obstetrics...